BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yeates L, Slatter MA, Bonanomi S, Lim FLWI, Ong SY, Dalissier A, Barberi W, Shulz A, Duval M, Heilmann C, Willekens A, Hwang WHY, Uderzo C, Bader P, Gennery AR. Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplant 2017;52:762-4. [PMID: 28092354 DOI: 10.1038/bmt.2016.351] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Schoettler M, Chonat S, Williams K, Lehmann L. Emerging therapeutic and preventive approaches to transplant-associated thrombotic microangiopathy. Curr Opin Hematol 2021;28:408-16. [PMID: 34534983 DOI: 10.1097/MOH.0000000000000687] [Reference Citation Analysis]
2 Laberko A, Gennery AR. Clinical considerations in the hematopoietic stem cell transplant management of primary immunodeficiencies. Expert Rev Clin Immunol 2018;14:297-306. [PMID: 29589971 DOI: 10.1080/1744666X.2018.1459189] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
3 Gavriilaki E, Ho VT, Schwaeble W, Dudler T, Daha M, Fujita T, Jodele S. Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. Exp Hematol Oncol 2021;10:57. [PMID: 34924021 DOI: 10.1186/s40164-021-00249-8] [Reference Citation Analysis]
4 Eftychidis I, Sakellari I, Anagnostopoulos A, Gavriilaki E. Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis. Expert Rev Hematol 2021. [PMID: 34388057 DOI: 10.1080/17474086.2021.1968823] [Reference Citation Analysis]
5 Higham CS, Shimano KA, Melton A, Kharbanda S, Chu J, Dara J, Winestone LE, Hermiston ML, Huang JN, Dvorak CC. A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients. Pediatr Blood Cancer 2022;69:e29641. [PMID: 35253361 DOI: 10.1002/pbc.29641] [Reference Citation Analysis]
6 Elfeky R, Lucchini G, Lum SH, Ottaviano G, Builes N, Nademi Z, Battersby A, Flood T, Owens S, Cant AJ, Young H, Greener S, Walsh P, Kavanagh D, Annavarapu S, Rao K, Amrolia P, Chiesa R, Worth A, Booth C, Skinner R, Doncheva B, Standing J, Gennery AR, Qasim W, Slatter M, Veys P. New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT. Blood Adv 2020;4:2418-29. [PMID: 32492158 DOI: 10.1182/bloodadvances.2019001315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Yang LP, Liu X, Zhang XH. [Advances in the diagnosis and management of transplant-associated thrombotic microangiopathy]. Zhonghua Xue Ye Xue Za Zhi 2021;42:693-9. [PMID: 34547882 DOI: 10.3760/cma.j.issn.0253-2727.2021.08.018] [Reference Citation Analysis]
8 Martínez-Muñoz ME, Forés R, Lario A, Bautista G, Bueno JL, de Miguel C, Navarro B, De Laiglesia A, Sánchez-Guerrero A, Cabrera JR, Duarte RF. Use of defibrotide to treat adult patients with transplant-associated thrombotic microangiopathy. Bone Marrow Transplant 2019;54:142-5. [PMID: 29899573 DOI: 10.1038/s41409-018-0256-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
9 Slatter MA, Gennery AR. Hematopoietic cell transplantation in primary immunodeficiency - conventional and emerging indications. Expert Rev Clin Immunol 2018;14:103-14. [PMID: 29300535 DOI: 10.1080/1744666X.2018.1424627] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
10 Carreras E; Barcelona Endothelium Team (BET). Vascular endothelial syndromes after HCT: 2020 update. Bone Marrow Transplant 2020;55:1885-7. [PMID: 32203255 DOI: 10.1038/s41409-020-0852-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Scordo M, Giralt SA. A key step towards setting a benchmark for tackling transplant‐associated thrombotic microangiopathy. Br J Haematol 2020;189:1006-9. [DOI: 10.1111/bjh.16507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Richardson PG, Palomo M, Kernan NA, Hildebrandt GC, Chao N, Carreras E. The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae. Bone Marrow Transplant 2021. [PMID: 34584241 DOI: 10.1038/s41409-021-01383-x] [Reference Citation Analysis]
13 Ikezoe T. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies. Int J Hematol 2021;113:34-44. [PMID: 32902759 DOI: 10.1007/s12185-020-02992-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 Pagliuca S, Michonneau D, Sicre de Fontbrune F, Sutra Del Galy A, Xhaard A, Robin M, Peffault de Latour R, Socie G. Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. Blood Adv 2019;3:2424-35. [PMID: 31409584 DOI: 10.1182/bloodadvances.2019000143] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
15 Hematopoietic Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association. [Chinese consensus on the diagnosis and management of transplant-associated thrombotic microangiopathy (2021)]. Zhonghua Xue Ye Xue Za Zhi 2021;42:177-84. [PMID: 33910301 DOI: 10.3760/cma.j.issn.0253-2727.2021.03.001] [Reference Citation Analysis]
16 Calabretta E, Moraleda JM, Iacobelli M, Jara R, Vlodavsky I, O'Gorman P, Pagliuca A, Mo C, Baron RM, Aghemo A, Soiffer R, Fareed J, Carlo-Stella C, Richardson P. COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. Br J Haematol 2021;193:43-51. [PMID: 33538335 DOI: 10.1111/bjh.17240] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
17 Ardissino G, Capone V, Tedeschi S, Porcaro L, Cugno M. Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy. Pharmaceuticals (Basel) 2022;15:845. [PMID: 35890144 DOI: 10.3390/ph15070845] [Reference Citation Analysis]
18 Kanunnikov MM, Rakhmanova ZZ, Levkovsky NV, Vafina AI, Goloshapov OV, Shchegoleva TS, Vlasova JJ, Paina OV, Morozova EV, S Zubarovskaya L, Kulagin AD, S Moiseev I. Conversion from calcineurin inhibitors to sirolimus in transplant-associated thrombotic microangiopathy. Clin Transplant 2021;35:e14180. [PMID: 33258122 DOI: 10.1111/ctr.14180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Laberko A, Aksenova M, Shipitsina I, Khamin I, Shcherbina A, Balashov D, Maschan A. Serious Hemorrhagic Complications After Successful Treatment of Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy With Defibrotide in Pediatric Patient With Myelodysplastic Syndrome. Front Pediatr 2020;8:155. [PMID: 32432059 DOI: 10.3389/fped.2020.00155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Gavriilaki E, Sakellari I, Anagnostopoulos A, Brodsky RA. Transplant-associated thrombotic microangiopathy: opening Pandora's box. Bone Marrow Transplant 2017;52:1355-60. [PMID: 28287636 DOI: 10.1038/bmt.2017.39] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
21 Altmann T, Slack J, Slatter MA, O'Brien C, Cant A, Thomas M, Brodlie M, Annavarapu S, Gennery AR. Endothelial cell damage in idiopathic pneumonia syndrome. Bone Marrow Transplant 2018;53:515-8. [PMID: 29335628 DOI: 10.1038/s41409-017-0042-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Richardson PG, Carreras E, Iacobelli M, Nejadnik B. The use of defibrotide in blood and marrow transplantation. Blood Adv 2018;2:1495-509. [PMID: 29945939 DOI: 10.1182/bloodadvances.2017008375] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
23 Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplant 2021;56:1805-17. [PMID: 33875812 DOI: 10.1038/s41409-021-01283-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Higham CS, Collins G, Shimano KA, Melton A, Kharbanda S, Winestone LE, Huang JN, Dara J, Long-Boyle JR, Dvorak CC. Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis. Blood Adv 2021;5:2106-14. [PMID: 33877298 DOI: 10.1182/bloodadvances.2020003988] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Betzmann D, Döring M, Blumenstock G, Erdmann F, Grabow D, Lang P, Binder G. Impact of serum insulin-like growth factor-1 on HSCT outcome in pediatric cancer patients. Transplant Cell Ther 2022:S2666-6367(22)01195-2. [PMID: 35405367 DOI: 10.1016/j.jtct.2022.03.027] [Reference Citation Analysis]
26 Slatter MA, Gennery AR. Advances in the treatment of severe combined immunodeficiency. Clinical Immunology 2022. [DOI: 10.1016/j.clim.2022.109084] [Reference Citation Analysis]
27 Carreras E, Diaz-ricart M. Early Complications of Endothelial Origin. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook. Cham: Springer International Publishing; 2019. pp. 315-22. [DOI: 10.1007/978-3-030-02278-5_42] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]